FMS - Fresenius Medical Care AG & Co. KGaA

NYSE - Nasdaq Real Time Price. Currency in USD

Fresenius Medical Care AG & Co. KGaA

Else-Kroner Strasse 1
Bad Homburg 61352
49 6172 609 0

IndustryMedical Care Facilities
Full Time Employees121,403

Key Executives

NameTitlePayExercisedYear Born
Mr. Robert Maurice Powell Jr.Chairman of the Management Board & CEO of Fresenius Medical Care Mgmt AGN/AN/A1955
Ms. Helen GizaCFO & Member of Management Board of Fresenius Medical Care Mgmt AGN/AN/A1968
Mr. Kent WanzekCEO of Global Mfg, Quality & Supply and Member of Management Board - Fresenius Medical Care Mgmt AGN/AN/A1959
Dr. Olaf SchermeierCEO of Global R&D and Member of the Management Board - Fresenius Medical Care Mgmt AGN/AN/A1972
Mr. Harry de WitCEO of APAC & Member of Management Board - Fresenius Medical Care Mgmt AGN/AN/A1962
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems for the treatment of ESRD; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides pharmacy services, vascular, cardiovascular, endovascular specialty, hospitalist, emergency, intensivist, medical cost management, ambulatory surgery center, health plan, urgent care, physician nephrology and cardiology, and ambulant treatment services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2019, it operated 3,994 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.

Corporate Governance

Fresenius Medical Care AG & Co. KGaA’s ISS Governance QualityScore as of December 7, 2019 is 7. The pillar scores are Audit: 10; Board: 7; Shareholder Rights: 1; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.